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Technical Research Progress Report 
June 30, 1986 
To 
The goals of our research program are: (1) to examine the biochemical mechanism responsible 
for the antihypertensive activity we have demonstrated for certain compounds· of our design; (2) to 
bioassay the potential antihypertensive activity of other compounds we have already designed and 
synthesized based on the ideas of this proposal; and (3) to correlate the · appearance of the 
hypotensive effect of certain of these compounds with their effects on endogenous catecholamine 
levels,- an index which can be used to monitor changes in adrenergic neuronal activity. 
Substantial progress has been made in all of these areas. The following paragraphs 
summarize our progress during this first year of the current project period. 
Uptake and Enzymatic Turnover in Chromaffin Granules. The most likely mechanism by which 
these neurotransmitter analogs are causing an antihypertensive effect in spontaneously hypertensive 
rats (SHR) is thought to involve uptake into neuronal cells, followed by uptake into 
neurotransmitter storage vesicles. After uptake, by virtue of their ability to act either as 
dopamine beta-monooxygenase (DBM) substrates or inhibitors, they effectively reduce the amount of 
norepinephrine (NE) stored in these vesicles and available for release and post-synaptic activation 
of adrenergic receptors. 
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We have chosen initially to look at uptake into neurotransmitter storage vesicles. Since t'his is 
the critical step in the overall process, by performing these eJr::periments first we can focus on the 
most promising compounds for subsequent testing in the more laborious whole-cell uptake and 
release experiments. Also, we are now utilizing a procedure. which incorporates the recent elegant 
work from David Njus' laboratory where it has been demonstrated that "ghosts" derived from 
chromaffin granules are a much better model for these types of uptake and conversion experunents. 
Using this chromaffin vesicle ghost protocol, we have now demonstrated uptake of the 
prototype selenium-containing analog, phenyl aminoethylselenide (PAESe), into these vesicular 
preparations. Furthermore, we have shown that the enzyme-dependent ascorbate recycling process 
we observed in free solution (see pp. 9-10 of original proposal for rationale) . does occur in these 
vesicle preps. We have demonstrated that uptake of PAESe into ghosts results in a ca. 70% 
reduction of vesicular ascorbate levels. In virtually identical experiments, we are now exammmg 
the effects of several of our sulfur-containing analogs on the vesicular uptake and conversion 
process. 
We chose to begin these vesicle studies by using the selenium-containing compound, PAESe, 
because of the sensitivity and ease with which we are able to measure changes in ascorbate levels 
within these ghosts using HPLC with electrochemical detection. For the work we propose to 
perform with the test compounds of the other classes, we must be able to acquire radiolabelled 
versions of the test compounds. To this end, we have set up a radiolabelling synthetic laboratory 
which yields ring-tritiated compounds of high specific activity. We have, to date, tritium-labelled 
one test compound, phenyl ethylenediamine (one of our N-dealkylating analogs). During the coming 
year, we plan to extend this work to the other classes of compounds using essentially the same 
protocols. 
Bioassay of Antihypertensive Activity. Vle have now demonstrated a chronic dose-dependent 
antihypertensive effect in SHR for compounds of two classes (olefinic and selenium-containing). We 
have developed a chronic dosing and measuring protocol for use with these compounds since 
preliminary tests indicated that there was a 24-48 hour latency between dosing and the beginning 
of the antihypertensive effect. This protocol allows us to follow groups of SHR (control and 
drug-treated) over a two-week period, with dosing on a daily basis and the measurement of blood 
pressure, heart rate, and body weight over the entire period. Using this new protocol, we have 
found that phenyl aminomethylethene (PAME, our prototypic · olefin-containing analog) and phenyl 
arr.inoethylselenide (PAESe, a selenium-containing analog) both exhibit a marked, dose-dependent 
antihypertensive effect with as much as a 50% reduction in blooc pressure and heart rate which 
begins ca. 48 hrs. after the first dose and extends for two weeks in both cases. 
Correlations with Effects on Endogenous Catecholamines: As an important adjunct to the 
above studies, we remove whole hearts at the end of the dosing period, and using HPLC with 
electrochemical detection, are able to demonstrate a marked change in sympathetic nerve-ending 
catecholamines in the drug-treated animals. We have found a >50% reduction in norepinephrine and 
a >70% reduction in epinephrine from hearts of animals treated with PAESe which correlates with 
the effects on blood pressure and heart rate already noted. In the case of PAME, these effects are 
ca. -54% for NE and -80% for EPI. \Vith both compounds we are also seeing a marked decrease in 
the weight of the hearts of those animals receiving the test compound. 'We think this may reflect 
a "blockage" of the developement of left ventricular hypertrophy which normally accompanies the 
etiology of hypertension, but have not conclusively proven this as yet. During the coming year 
we plan to further refine the bioassay using, for example, implanted osmotic pumps to 
continuously deliver compound doses in SHR, and plan to extend this bioassay to other compounds 
of different classes. 
Other Findings: One unusual and unexpected outgrowth of the examination of the the 
selenium-containing compounds was our observation that SHR dosed with PAESe dis.played a loss 
of whole-body weight as a consequence of the drug dosing. We have now shown that this weight 
loss is not due to a ·toxic effect of the com,pound, and that the marked hypotension noted is not 
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related to this we1ght loss. Instead, we have prehmrnanly demo~strated that a potent anorc::xxc 
effect (a CN S effect) occurs in addition to the: drug's effect on the peripheral adrenergic nervous 
system. We have adapted a standard "Skinner box" technique to the quantitation of this anorexic 
effect of PAESe, and see, at least preliminarily, a 70-80% reduction in the test animal's ingestion 
of food pellets in response to drug dosing. This effect will be further studied in the coming 
year. 
Finally, we have developed a new isolation method for enzymological quality DBM as an 
outgrowth of our work with bovine adrenal chromaffin granules. · Nearly all DBM enzymological 
studies are based on an old, but tried and true method developed by Ljones, et al. (1976). 
Enzyme preparations based on this preparative technique have yielded enzyme with specific 
activities of 10-3 5 Units per milligram of protein isolated. Using the purified chromaffin granules 
which are necessary for our uptake experiments, we have developed a short, fast preparative 
method using new FPLC techniques which yield enzyme of 60-85 Units per mg, from much less 
starting material. \Ve have found that the enzyme we so isolate is identical kinetically to that 
which we isolated by the older, more labor-intensive method. During the coming year we will 
further refine this method and, in particular, will be able to increase its yield by including steps 
designed to include in the isolate membrane-bound DBM which comprises nearly 50% of the 
vesicular enzyme. 
f.LAt{~QILit!~QM.lli.~E.6E.: As in any research, the first year has involved the 
developement, adaptation, and "fine-tuning" of experimental protocols to the particular needs of the 
research project. Our findings of the past year have resulted in the establishment of simple and 
effective procedures for the characterization, in SHR, of the effects of test compounds on systemic 
blood pressure, heart rate, body weight, heart weight, and heart catecholamine levels. These 
procedures will be used for test compounds of the other classes. A very well-respected researcher 
in the area of adrenal chromaffin cell culture, Dr. Norman Kirshner at Duke University, has 
expressed some interest in the work of this project, and has agreed to train our technician as well 
as one graduate student this summer in the culture of these cells, which is the next major step m 
the demonstration of the mechanistic explanation of the antihypertensive effects of these 
compounds. Finally, we will begin this summer to examine the pharmacology of the uptake of 
tritium-labelled test compounds into the chromaffin cell "ghosts", where we have (in the case of 
the PAESe compounds) already demonstrated intra-vesicular effects. 
S.H. Pollock, H.H. Herman, M. Dillard, and S.W. May, "The Vascular and Antihypertensive 
Activity of Sulfur Analogs of Phenylpropylamine, Novel Substrates for Dopamine 
· Beta-Monooxygenase", (under submission to I. Cardio. Pharm.>. 
Admittedly, this initial year has not led to the immmediate publication of any significant 
results. However, the work performed in the past year has led to a number of significant 
findings which will be organized into manuscripts for submission in the next months. These 
include: 
(1) Demonstration of the antihypertensive act1v1ty of PAESe in SHR with correlations to its 
effects on heart rate, heart weight, and catecholamine levels. 
(2) Demons~ration of the antihypertensive activity of PAME in SHR with correlations to its 
effects on heart rate, heart weight, and catecholamine levels. , . 
(3) Demonstration of ascorbate depletion in chromaffin granule ghosts in response to P AESe. 
(4) A study of the anorexic effects of PAESe in SHR and normal rats. 
(5) Preparatioi?: .of DBM of unusually pigh specific activity from chromaffin granules. 
, I 





0 ~) • - t-..5 rj 
t . 
&~Amen can Heart 
V Association 
Research Programs 
7320 Greenville Avenue 
Dallas, TX 75231 
Reference Number _ 8_5_-_1_2_8_6_ 
N f I 
. Heath H. Herman, Ph.D. 
arne o nvest1gator ---------------------------------
Senior Research Scientist 
Present ~cademic Position Ti~e ~-----------------------------
Georgia Tech s h 1 f Ch · Institution---------------~ Department ~---c_o_o __ 0 ___ e_m_l_s_t_r..::..y ___ _ 
Title of Current Research __ B_i_o_a_s_s_a_y_o_f_N_o_v_e_l_An_t_i_h_y_p_e_r_t_e_n_s_i_v_e_s _____________ _ 
7-86 
Period Covered by this Report -------------- 6-87 
From 
1. Honors, Citations, or Special ~wards Received During Year 
None 
2. Students in Training (Pre- and Postdoctoral) 
Alise Edwards, M.S. candidate (entered 9/83) 
Melanie Ciccarello, M.S. candidate (entered 9/84) 
3. Grant Support This Fiscal Year (Source, ~mount) 
Only National AHA, $33,000 
4. Membership in One or More ~H~ Scientific Councils (List) 
None 
Technical Research Progress Report 
To 
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Collen Beard, Ph.D. candidate enter~~ 85 : 
(9/86) 
The goals of our research program are: (1) to examine the mechanisms responsible for the 
antihypertensive activity we have demonstrated for certain novel compounds; (2) to bioassay the 
potential antihypertensive activity of other novel compounds; and (3) to correlate the appearance of 
the hypotensive eff('!ct of certain of these compounds with their effects on endogenous 
catecholamine levels, an index which can be used to monitor changes in adrenergic neuronal activity. 
Substantial progress has been made in all of these areas. The following paragraphs summarize our 
progress during this second year of the current project period. 
Uptake and Enzymatic Turnover in Chromaffin Granules. In our original proposal we hypothesized 
that the mechanism by which these neurotransmitter analogs were causing an antihypertensive effect 
in spontaneously hypertensive rats (SHR) was through neuronal uptake, followed by uptake into 
neurotransmitter storage vesicles. After uptake, by virtue of their ability to act as dopamine 
beta-monooxygenase (DBM) substrates, they would effectively reduce the amount of norepinephrine 
(NE) stored in these vesicles and thus lower the amounts of NE available for release and 
post-synaptic activation of adrenergic receptors. We now have evidence which suggests that while 
this hypothesis is operative in the case of the sulfur-containing class, compounds of the 
selenium-containing class seem to exert their effects more by the lowering of vesicular ascorbate 
levels. 
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As noted in the 1986 progress report, we have utilized chromaffin granule "ghostsu as our test 
model for neurotransmitter vesicles. While this model has been used extensively in the past by 
neurochemical investigators and is an excellent one for our purposes, we discovered late in 19 86, t 
our chagrin, that one of the more well-respected researchers in this field had reported that ghost 
membrane DBM was unable to utilize ascorbic acid as · a cofactor, suggesting that the enzyme. was 
very different from the more well-characterized "soluble" DBM. Since all of our experimental 
plans depended on the presence of DBM with the expected ·characteristics, we were forced to 
re-investigate the enzymatic properties of ghost membrane DBM. In a report recently submitted t~ 
.L lli2L ~hem., we have conclusively shown that membrane-bound DBM possesses properties 
identical to those of the more-commonly-studied soluble enzyme, and does, in fact, utilize ascorbi 
acid with great facility. This work, while something of an "aside" to the purpose of this grant, 
is a significant addition to the body of knowledge concerning adrenergic neurotransmitter synthesis 
since recent literature has shown that adrenergic neurons may possess only the membrane-bound 
form of this enzyme. The demonstration of the near-identical functioning of soluble and 
membrane-bound DBM re-establishes the connection between in vitro enzymology and in vivo 
functional activity of DBM. 
Using this chromaffin vesicle ghost method, we have now demonstrated uptake and conversion < 
the prototype sulfur-containing analog, phenyl aminoethylsulfide (PAES), into these vesicular 
preparations. We have been able to demonstrate the accumulation in isolated vesicles of the 
sulfoxide product expected from DBM oxygenation of PAES. Furthermore, we have demonstrated 
that the uptake and oxygenation of PAES in ghosts results in a ca. 50% reduction of vesicular 
norepinephrine levels when ghosts are incubated in the presence of both dopamine and P AES. 
These results suggest that our hypothesis as to the ability of these compounds to compete in 
vivo with dopamine for enzymatic oxygenation may likely be the actual mechanism of their 
antihypertensive activity. 
Again using this chromaffin granule ghost model, we have now demonstrated the facile uptake 
of phenyl arninoethylselenide (PAESe) into the vesicles. In contrast to our work above with the 
sulfur analog, we were unable to detect the oxygenated product (P AESeO) within these vesicles. 
Instead, we have now shown that intra-vesicular ascorbate is virtually completely used up in the 
process of PAESe oxygenation. As a consequence of this recycling of PAESe (see pp. 9-10 of the 
original proposal for rationale), norepinephrine synthesis and storage is drastically curtailed in 
these vesicles. Thus, the selenium-containing class of analogs appear to exert their effects more ~ 
their ascorbate-depleting properties than by their competition with dopamine for DBM oxygenatior 
This is distinctly different from the effects exerted by the sulfur-containing compounds. 
Bioassay of Antihypertensive Activity. We have now performed extensive bioassays of the 
antihypertensive activity in SHR for compounds of both the sulfur- and selenium-containing 
classes. In the case of the sulfur analogs, this work is detailed in a manuscript now accepted fo 
publication in L Cardiovasc. f_harmacol. Briefly, we show therein that four different analogs of 
that class possess significant antihypertensive activity, with the alpha-methylated analog possessin1 
the most potent activity. This latter analog (MeP AES)" was shown to exert a potent chronic 
antihypertensive effect in SHR. In more recent work, we have shown that only one enantiomer o ~ 
MePAES is an indirect sympathomimetic and exerts an antihypertensive effect, with the other 
enantiomer being n'early completely inert. 'This startling finding buttresses our hypothesis as to 
the need for neuronal uptake for activity, since other work has shown that the racemic MePAES 
binds unusually tightly to neuronal reuptake receptors. In ongoing work, we are trying to 
determine whether one isomer blocks the uptake receptor while the other passes through, or 
whether only one isomer interacts with the receptor at all. 
In the· case of the selenium-containing analogs, we have now demonstrated a very potent chroni~ 
antihypertensive activity for PAESe in SHR. This activity is accompanied by a substantial decrea: 
in heart rate, a very unusual finding since adrenergic reflexes normally increase heart rate to 
compensate · for the hypotensive effect. At the conclusion of these chronic assays, we found that 
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SHR treated with PAESe had significantly lower heart weights than the controls, suggesting that 
the ventricular hypertrophy which accompanies the development of hypertension had been negated 
by the drug treatment. In addition, we now have shown that a completely unexpected anorexigenic 
effect develops in response to treatment with P AESe. This effect results in lower food 
consumption and a dose-dependent loss of body weighf which is definitely not a result of toxic 
side effects. We have shown that blood enzymes, blood electrolytes, and blood glucose are ~orma] 
or below normal in chronically- treated SHR. This work is detailed in a manuscript recently 
submitted to L Pharmacol. Exptl. Ihu., 
Correlations with Effects on Endogenous Catecholamines: As an important adjunct to the above 
studies, we remove whole hearts at the end of the dosing period, and using HP LC with 
electrochemical detection, are able to demonstrate a marked change in sympathetic nerve-ending 
catecholamines in the drug-treated animals. We have found a >50% reduction in norepinephrine and 
a >70% reduction in epinephrine from hearts of animals treated with PAESe which correlates with 
the effects on blood pressure and heart rate already noted. In the case of PAES, these effects are 
ca. -34% for NE and -60% for EPI. Unexpectedly, we do not see a corresponding rise in dopamine 
levels which would be expected if NE synthesis is retarded. Since most of our heart samples are 
derived from chronically-treated SHR, we suspect that changes in dopamine levels may only be 
apparent in short time periods after dosing. However, since these findings are quite different from 
the literature reports on the effects of DBM inactivators, we need to thoroughly investigate this 
effect. It is our opinion that since these compounds do not inactivate DBM, that we may see 
effects on catecholamine levels which are different from the findings with DBM inhibitors. 
Chromaffin Cell Culture: As stated in our original proposal, we intend to extend the findings in 
neurotransmitter vesicles to an examination of the effects of c.ertain classes of compounds in whole 
cells. Adrenal medullary cells (chromaffin cells) are an excellent model for ·adrenergic neuronal 
transmitter studies. Accordingly, over the past 6 months, we have set up a complete tissue 
culture lab. Progress in this area has been rather halting for a number of reasons. Primary cell 
culture is unusually susceptible to contamination, particularly because of the necessity to gather 
our material at a somewhat distant meat packing facility. In addition, we have had great di£ ficu 1 ty 
in digesting adrenal medullae with collagenase without either low cell yields or high fibroblast 
contamination. However, we now have in hand a successful experimental protocol which yields a 
high number of chromaffin cells which are viable in culture for periods of 14-18 days. 
Experiments with these preparations will commence soon. 
Other Findings: Vve have developed two new classes of DBM substrates and inhibitors. These 
classes involve the replacement of the terminal primary amine f uctionality normally required for 
binding to DBM. In place of the amine, we have substituted imidazole or pyrazole rings. While 
these changes may seem relatively unimportant, they have been pursued because of the possiblity 
of developing possible adrenergic receptor agonists which will be activated only after the 
oxygenation by DJiM of inactive precursors. This would represent an new direction for our general 
tactic of designing physiologically- inactive precursors which are activated only by neuronal DBM. 
The imidazole-containing compounds are particularly interesting because of their similarity in 
structure to clonidine, an important clinical antihypertensive. This work was published in 
Biochem • .1 in 1986 • . 
Finally, we hav~· developed a new ~lass of ascorbic acid analogs. These compounds are designed 
to participate in the donation of electrons to DBM just as ascorbate does, but can either: (1) 
form brightly-colored oxidation products which may be useful in enzymology or in histological 
studies; or (2) inactivate DBM during the course of enzymatic catalysis. These ascorbate analogs 
have only recently been developed, and much additional work will be needed before their true 
utility becomes apparent. 
PLAN~QR THE CQMIN§_Y£.AR: The work of the past two years has been quite successful. 
Several of the goals of the original proposal have been successfully met. Yet remaining is the 
demonstration of cellular uptake, conversion and release •. This will be the major focus of the 
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coming year. Since we have now a working cell culture laboratory, we think that our propsed 
experimentation can be successfully carried out. Other work will be focused on the startling 
findings with respect to the unusual enantiometric specificity of the alpha-methylated analogs for 
adrenergic reuptake receptors. 
"Ascorbate Depletion as a Consequence of Product Recycling During Dopamine Beta-Monooxygenase 
Catalyzed Selenoxidation", s.w. May, H.H. Herman, S.F. Roberts, and M.C. Ciccarello, 
Biochemistry, 2..2. 1626-1633 (1986). 
"Interaction of Dopamine Beta-Monooxygenase with Substituted Imidazoles and Pyrazoles: 
and Inhibition", S.R. Sirimanne, H.H. Herman, and S.W. May, Biochem. L, .lib 227-233 
Catalysis 
(19 8 6). 
"The Antihypertensive Activity of a Selenium-Containing Analog of Phenylpropylamine", S.H. 
Pollock, H.H. Herman, S.W. May, L.C. Fowler, and A. Edwards, First Annual Symposium_Qg 
Cardiovascular Research, American Heart Association, Georgia Affiliate, (19 86). 
"Cardiovascular Effects of Phenyl-2-Aminoethyl Sulfide (PAES)", M. Bayorh, R.\V. Trottier, S.H. 
Pollock, H.H. Herman, and S.W. May, Third Annual Nabrit Symposium, Atlanta University and 
Morehouse School of Medicine, (19 86). 
H.H. Herman, S.H. Pollock, L.C. Fowler, and S.W. May, "Demonstration of the Potent 
Antihypertensive Activity of Phenyl Aminoethylsulfides", L Cardio. ~harm., in press, (1987). 
"The Antihypertensive Activity of a Selenium-Containing Analog of Phenylpropylamine", S.H. 
Pollock, H.H. Herman, S.W. May, and L.C. Fowler, Fed. Proc., Fed. Amer. Soc. Exptl. Biol., .i.Q., 
12 9 0' ( 19 8 7). 
"Antihypertensive Activity and Ascorbate Depletion via Product Recycling by DBM-Targeted 
Selenides", S.W. May, H.H. Herman, S.H. Pollock, L.C. Fowler, K. Wimalasena, and M.C. 
Ciccarello, Fed. Proc., Fed, Amer, Soc, Exptl. Biol., ~ 1940, (1987). 
"Mechanistic and Specificity Studies on Dopamine Beta-Monooxygenase Catalysis", K. Wimalasena, 
S.R. Sirimanne, H.H. Herman, and S.W. May, Fed. Proc., Fed, Amer. Soc, Exptl. Biol., ~ 2043, 
(19 87). 
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18. Typed Name and TrtJe of Principal Investigator Signatttr~ Date 
Dr. Heath H. Herman, Senior Research Scient st J tj/Sj 'f/ 
19. T~d Na~e t"d ¥1jle of Fiscal Officer ~inn~t••rc 
,.,/' ~ 
Date 
~v1 V ~e t 1~ctor . j{,&Jfs-7 ran s & on r~c s ccount1ng 
20. Preparer's Name and Phone Number 
Val eri·a D. Henderson ( 404 ) 894-5523 
1 
.Supplemental SchbJules 




(If none, so indicate) 
1. Lydia Fowler GRNChem Tech I $5,436 • .91 
2. Gerald E. Moon Student Asst. 1,365.17 
3. Frederick K. Young Chern Tech I 12,880.56 
4. 
5. 
Subtotal $19,682.6 ~ 
6. Social Security, Retirement, Fringe Benefits 4 '720. 2 ~ 
Total $24,402.91 
B. Expenditures for Travel (See Awards Statement) 
Date of Travel Name of Traveler and Destination Amount 




Total $ 473.55 
C. Expenditures for Equipment 
lte~ize all purchases of $500 or more Amount 
1. 








9. Total of equipment items which cost less than $500 each 229.2P 
Total $ 229.20 
2 
. Supplemental Schedul (Continued) 
D. Expenditures for Supplies (List major types) 
1. Filterware, Piplets, Viles & Spectra Mesh 
2. Rats 
3. Carbon Dioxide 
4. ~arbon Dioxide (Cylinder Deposit) 
5. Instromark Tape and Handles 
6 . . Glands 
7. Salt Solution 













F. Expenditures for Other 
(Itemize all other expenditures not reported under above schedules) 





G. Summary of Expenditures 
A. Expenditures for Personnel 
B. Expenditures for Travel 
C. Expenditures for Equipment 
D. Expenditures for Supplies 
E. Expenditures for Publication Costs 











































~upplemental Schedulet -;ontinued) 
H. Obligations Incurred- Current (Itemize) (To be liquidated in following fiscal period) 









8. 100/o overhead 
Total $ N/A 














Total Obligations Paid - Enter on page 1, line 9 $ N/A 
4 
Georgia Teen 
July 16, 1990 
Ms. Rosario Sinha 
American Heart Association 
Division of Research Awards 
7320 Greenville Avenue 
Dallas, TX 75231 
SUBJECT: Grant-In-Aid No. 85-1286 
Dear Ms. Sinha: 
Office of Grants :tnd Contracts A~.Younting 
Georgia Institute of Technology 
Hinman Building 




Review of our sponsored operations has revealed that 
the final Expenditure Report for Grant-In-Aid 85-1286 has not 
been submitted. Enclosed in triplicate is the fihal 
Expenditure Report for this project and Georgia Tech Research 
Corporation's Check No. 22224 to refund the unexpended 
balance for this project in the amount of $179.75. The 
difference between the refund and Line 15 of the report is 
the result of a cost correction in the amount of $6.98 
related to an unexpended balance during the FY 1986-87 report 
period. 
If you require any additional information, please 
contact either Ellen Scott at 894-6759 or Linda Gill at 894-
5526. 
Sincerely, 
David v. Welch 
Director 
cc: Dr. Heath H. Herman, Chemistry 0400 
Dr. K. E. Barefield, Chemistry 0400 
Mr. R. M. Bell, GTRC 0415 / . 
Mr. D. Hutchison, OCA 042ovr 
File G-33-653/24-6-R5988-0AO 
A 1 ·nir of rhe l'nin:rsir\· "\''tl'm nf Gt' '>r.~ i.! 
·: .. 
. 
I . • -·. .t . . . . . . . 
)Expenditures Report ror·. . . QArnerlcan Heart 
Grants-In-Aid - · 
.. · Association 
National Center 
1.· Name of PrtncipaJ IIMitigalor, lnllltullon and ~ -·· 2. AHA Code 3.lnll Code 
85-1286 
Dr. Heath H. Herman .. 
School of Chemistry 4. Fllcal Period 
Georgia Institute of Technology Ftan: 07l0ll§§ '1»: Q6l30l89 
225 North Avenue 
Atlanta. GA 10'\'\, 
5. Funds Authorized tor Thla Fllc:af P8riod (AI Fer~ Slll8mlnQ • 2,035.65 . 
e. ldd: Obl'egatlona from PI'8Yioul P8riod (Schedule H Lui 'Mr'a Repott) • . . ' 
7. 1bCal Nailable tor Disbursement This Filcal P8rlod (Add lines 5 and 8) ' 
2,035.65 
a Less: 'baJ Expended tor Thil Filcal P8rlod (Schedule G) • 1,693.53 
I. Add: Previous P8rlod Obligations PaJd This Filcal Period (Schedule ~ • N/A -· · 
1Q Subt1Cal (Add Dries 8 and I) • 1,693.53 
11. OYerhead (10% of line 10) • 169.35 -~ 
12. 10taJ (Jdd lines 10 and 11) • 1,862.88 
13. Balance Befor8 Current Obligations (Sublrad lne 12 from lne 7) • 172.77 -
M. Current Obregadona - See 10tal (Schedule H) • N/A 
15. Free and Unobl1gated Balance (Sublnld line 14 from lnl13) • 172.77 
·~ -
1& Please lnltlll Applopri8l8 Eklc 
I I I wish to rwtaJn the balance (line 15) to conllnue the projed (s.. lnllrudlonl reganlng 
Unexpended Fundi). 
. 
I I I I wish to retum the balance ($10 or men). Check II enclosed. 
I I I wish to retain $7,500 ~ the balance and return the remalndet 
17. We herel7/ certify thai this report is true and correct to the belt of our knowledge and thai a1 axpendltures and obligl-
t1ons reported herein have been made In accordance with the appropriala AHA grant policies and for the purposes Ill 
torth In the application and the Grant-in-Aid Agree,.,.. bm. 
l I ( 
1& 1Yped Name and 11tle of Principallnwstigalor Sign .. ..J . L Jl I ' )~ fd' Dr. Heath B. Herman, Senior Research Scient 1st. 
19. 1Yped Name and Title ~ Fiscal Offtc:er -• r 1 
~ . -- ~ I c-'1 VWW"--· 
David V. Welch, Director, Grants & Contrac s Account1ng - ~ - 1-/C,.,qf) . 
20. Preparer's Name and Phone Number 












" S.II*Aal • 
I. Social Security, Retirement, Fringe Benefits .... • N/A 
a Expenditures for 1i'avel (See ~ Statement)· . 






1Jtll • N/A . 
C. Expenditures for Equipment 







5. .. . 
7. .~ 
a 
1. ToCaJ of equipment items which cost less than $500 each 




Supplemental Schedules ( ~ .Jntinued) 
D. Expenditures tor Supplies (list major types) Amounl 
1. Fluid cell for LDC-UV s 1,400.0) -
















Total, s 1,478.03 
E. Expenditures for Publication Costs Amount t 
I 
1. ~1-f..IA~ s 171i on 
2. 22.od 
\s E Sjx lab p~acessiDg I l&.ad 
Total! s 215.50 
1
F. Expenditures for Other 
(ftemize all other expenditures not reported under abcMt schedules) Amount 





~ Total s ~UA 
l. Summary ~ Expenditures Amount 
A. Expenditures for Personnel s N/A 
a Expenditures for Trawtf ~~-
C. Expenditures for Equipment N/A 
jo. Expenditures for Supplies - 1,478.03 
;e. Expenditures for Publication Costs 215.50 
;F. Expenditures for Other N/A 
Total ~ 1.693.53 
Supplemental Schedules (Continued) 
H. Obligations Incurred- Current (Itemize) (To be liquidated in toiiONing fiscal period) 













10% owrhead as not permatted until items are patd Total 1 s I NA 
I. Prior Period Obligations Paid (Itemize) 
·Date Date Item Amount Incurred Paid 
1. s 
2. 







Total Obligations Paid - Enter on page 1. line e s W/A. 
GEORGIA TECH RESEARCH CORPORATION 
GEORGIA INSTITUTE OF TECHNOLOGY 
ATLANTA, GA 30332 
Cas The Citizens and Southern National Bank Atlanta. DeKalb CoUDty. Geoi'Jia 
NO - 22224 
64-1278 
611 
______ J~u~l~y~9~ _______ 19 _2Q__ 




American Heart Association 
Division of Research Awards 
7320 Greenville Avenue 
Dallas, Texas 75231 
DETACH AND RETAIN THIS STATEMENT 
COUNTERSIGNED 
TH£ ATTACH£0 CH£CK I S IN I"AYM£NT OF IT£MS OE:SC .. IB£0 •t:L.OW. IF NOT CORR£CT .I"L£AS£ NOTI FY US I" .. OMPTL.Y . NO R£CEII"T OESI .. EO. 









Refund per request 
G33-653 
OTHER TOTAL 
au• 
NUM8CIII 
10204 
P',I,C.A. 
AMOUNT DP' 
INYDICC 
WITHHOLD• 
lNG TAX 
DEDUCTION. 
8TATE 
TAX 
DEDUCTIDN8 
NCT 
PAY 
AMOUNT PAID 
$179.75 
